Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 5, doi. 10.7326/ACPJC-2016-165-2-006
- By:
- Publication type:
- Article
Works matching IS 10568751 AND DT 2016 AND VI 165 AND IP 2
Results: 10
1
2
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 10, doi. 10.7326/ACPJC-2016-165-2-011
- By:
- Publication type:
- Article
3
In adults >65 years of age, antidepressant drugs were not linked to increased risk for CV outcomes.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 9, doi. 10.7326/ACPJC-2016-165-2-010
- By:
- Publication type:
- Article
4
Review: Some NSAIDs, notably diclofenac, improved knee or hip pain and function in osteoarthritis vs other NSAIDs.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 8, doi. 10.7326/ACPJC-2016-165-2-009
- By:
- Publication type:
- Article
5
Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 7, doi. 10.7326/ACPJC-2016-165-2-008
- By:
- Publication type:
- Article
6
Combination candesartan-HCTZ did not reduce major CV events in patients at intermediate CV risk.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 6, doi. 10.7326/ACPJC-2016-165-2-007
- By:
- Publication type:
- Article
7
Long-term antibiotics after ceftriaxone did not improve quality of life in persistent Lyme disease.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 4, doi. 10.7326/ACPJC-2016-165-2-005
- By:
- Publication type:
- Article
8
Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 3, doi. 10.7326/ACPJC-2016-165-2-004
- By:
- Publication type:
- Article
9
In adults, quitting smoking abruptly improved abstinence more than quitting gradually.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 2, doi. 10.7326/ACPJC-2016-165-2-003
- By:
- Publication type:
- Article
10
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 1, doi. 10.7326/ACPJC-2016-165-2-002
- By:
- Publication type:
- Article